Investor's Business Daily on MSN
Alkermes shows improved relative strength; still shy of benchmark
A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?
Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...
Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is ...
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.
Investor's Business Daily on MSN
Alkermes earns RS rating upgrade
Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Incumbent U.S. Reps. Dave Joyce and Michael Rulli, the two Republicans who represent the Mahoning Valley, have significant ...
Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and ...
The gut microbiome’s neuroactive potential is linked to cognition and depression in Chilean older adults, per analysis of 153 Chilean older adults with cognition concerns ...
Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results